Centauri Therapeutics: Focused on the discovery and development of novel molecules targeting life threatening diseases.




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Centauri Therapeutics: Focused on the discovery and development of novel molecules targeting life threatening diseases.
Released on: January 23, 2017. © PharmaVentures Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    The Alphamer technology is based on "programmable immunity" in which chemically synthesised molecules redirect naturally occurring antibodies to selected pathogens to fight the infection.
  • Summary
  • Participants
  • Company
The Alphamer technology is based on "programmable immunity" in which chemically synthesised molecules redirect naturally occurring antibodies to selected pathogens to fight the infection. The molecules have two distinct parts: one end binds a cell-surface target on the pathogen using an aptamer whereas the other end presents specific epitopes that attach to the circulating antibodies. It has been demonstrated that Alphamers have the potential to redirect pre-existing antibodies to bacteria in a specific manner and trigger an immediate antibacterial immune response, so clearing the infection.
Mike has 15 years' experience in Pharma R&D, having worked for both Roche and Pfizer. Mike has worked across the Research and Development spectrum and whilst at Pfizer he helped successfully develop a novel therapy for treatment of HIV infection. Mike also headed up Pfizer's Opportunities for Partnership in Medicine (OPM) Research Unit and was a member of the Research Leadership Team at Pfizer's R&D UK Laboratories. Mike trained in Molecular Biology and Biochemistry at University of Durham, obtained his PhD at Warwick University and then completed a postdoctoral research fellow at St George's Hospital Medical School.
Centauri Therapeutics is a UK-based biotechnology company focused on the discovery and development of novel molecules targeting life threatening diseases.